The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score‐matched analyses
Journal of Hepato-Biliary-Pancreatic Sciences · 2023
DOI: 10.1002/jhbp.1313 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Hepato-Biliary-Pancreatic Sciences, 2023. Verfasst von Won-Gun Yun und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer Research Institute, Seoul National University College of medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Pancreatic Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: Institute for Information and Communications Technology Promotion.
Abstract (Originalsprache)
Background
In an era of more effective chemotherapy for pancreatic ductal adenocarcinoma (PDAC), the paradigm of local treatment is changing. However, the efficacy of local treatment in patients with isolated liver metastasis remains unclear. Therefore, we aimed to evaluate the effectiveness of pancreatectomy ± local treatment for metastasis (cytoreductive surgery) in PDAC patients with isolated synchronous liver metastasis.
Methods
In total, 239 patients with isolated liver metastasis were extracted from Seoul National University Hospital (SNUH). For comparison, another 12 637 patients were extracted from the National Cancer Database (NCDB). Propensity score matching was performed to minimize confounding in both cohorts. Survival analyses stratified by the treatment delivered were performed using Kaplan–Meier estimates and log‐rank tests.
Results
In the SNUH cohort, the median (interquartile range) survival was 20.5 (13.0–42.0) months for patients who underwent cytoreductive surgery plus chemotherapy versus 12.0 (10.0–18.0) months for those who received chemotherapy alone ( P < .001). With the NCDB cohort, the median (interquartile range) survival was 15.6 (8.9–31.2) months for patients who underwent cytoreductive surgery plus chemotherapy versus 7.4 (3.4–13.2) months for those who received chemotherapy alone ( P < .001).
Conclusion
Patients with isolated synchronous liver metastasis should be considered for cytoreductive surgery in addition to effective chemotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery and Cancer Research Institute, Seoul National University College of medicine, Seoul, Korea.
- Division of Gastrointestinal and Endocrine Surgery, Department of Surgery, Columbia University Vagelos College of Physicians and Surgeons, New York, New York, USA.
ORCID-Profile: Won-Gun Yun, Youngmin Han, Mirang Lee, Hye-Sol Jung, Alexander S Thomas, Wooil Kwon, Jin-Young Jang
Förderung
- Institute for Information and Communications Technology Promotion
Zitieren
APA
Yun, W. G., Han, Y., Lee, M., Cho, Y. J., Jung, H. S., Thomas, A. S., Kluger, M. D., Kwon, W., & Jang, J. Y. (2023). The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score‐matched analyses. Journal of Hepato-Biliary-Pancreatic Sciences. https://doi.org/10.1002/jhbp.1313
Vancouver
Yun WG, Han Y, Lee M, Cho YJ, Jung HS, Thomas AS, et al. The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score‐matched analyses. Journal of Hepato-Biliary-Pancreatic Sciences. 2023. doi:10.1002/jhbp.1313
BibTeX
@article{Yun2023,
author = {Yun, Won-Gun and Han, Youngmin and Lee, Mirang and Cho, Young Jae and Jung, Hye-Sol and Thomas, Alexander S and Kluger, Michael D and Kwon, Wooil and Jang, Jin-Young},
title = {The role of local treatment including pancreatectomy for pancreatic ductal adenocarcinoma patients with isolated synchronous liver metastasis: Propensity score‐matched analyses},
journal = {Journal of Hepato-Biliary-Pancreatic Sciences},
year = {2023},
doi = {10.1002/jhbp.1313}
}
EUVIMED